The Emmes Company, LLC

The Emmes Company, LLC, a for-profit limited liability company headquartered in Rockville, Maryland, provides clinical research support services to the federal government as a prime contractor on multi-million-dollar indefinite delivery vehicles and definitive contracts, with 94 percent of recent awards held at the prime level and no SBA set-aside designations across its portfolio. Emmes operates through two subsidiaries—Essex Management LLC and Emmes Endpoint Solutions, LLC (a self-certified small disadvantaged business)—and delivers biostatistical analysis, data management, clinical trial coordination, regulatory support, protocol monitoring, and data coordinating center operations across the National Institutes of Health and related federal agencies.

The company's federal footprint concentrates heavily within NIH institutes. The National Institute on Drug Abuse leads by award count (90 awards, $479.9 million combined potential value), followed by the National Institute of Allergy and Infectious Diseases (44 awards, $1.67 billion), the National Institute of Child Health and Human Development (41 awards, $192.9 million), the National Heart Lung and Blood Institute (39 awards, $63.4 million), and the National Cancer Institute (14 awards, $386.8 million). However, potential value concentration diverges sharply: the National Institute of Diabetes and Digestive and Kidney Diseases anchors the portfolio with 7 awards carrying $3.98 billion in combined potential value, reflecting single large-scale registry and research infrastructure contracts. The top five customers by potential value account for 92 percent of combined dollars. Recent prime awards include a $50.9 million cost-plus-fixed-fee definitive contract from the National Cancer Institute for logistical and IT support to the NCI Central Individual Review Board (awarded September 1, 2024, through August 31, 2029); a $49.5 million single-award IDIQ for clinical coordinating center operations under NIDA's Clinical Trials Network (awarded August 15, 2024, through August 14, 2029); a $30.1 million definitive contract from the National Eye Institute for vision clinical trials and epidemiology research development and statistical design (awarded November 1, 2021, through October 31, 2026); and a $16.5 million definitive contract from the National Institute of Mental Health for data coordinating center services supporting the National NeuroHIV Tissue Consortium (awarded August 7, 2023, through August 6, 2027).

Emmes holds primary positions on five large parent vehicles. The NIDA Data, Statistics, and Clinical Trial Support Center IDV (N01DA-22-2253), valued at $44.3 million with ceiling through September 4, 2027, has generated 26 delivery orders totaling approximately $29.5 million as of May 2025 for substance abuse treatment research across opioid use disorder, stimulant use, cocaine use, and HEAL (Helping to End Addiction Long-Term) initiatives. The Clinical Coordinating Center for NIDA's Clinical Trials Network, a $49.5 million single-award IDIQ through August 14, 2029, supports multi-site clinical trials and data coordinating center functions with six task orders issued. The Clinical Research Support and Collaboration for NHGRI Protocols IDIQ, a $4 million single-award vehicle with ultimate completion December 31, 2026, enables flexible task-order-based delivery of biostatistical analysis, data management, regulatory support for IND/IDE submissions, and Data Safety and Monitoring Board services for genomic medicine research. Additional vehicles include a $1.12 million IDV for All of Us Research Program IRB support (ultimate completion March 24, 2023, with $4.03 million in issued delivery orders) and the Multiple Study Data Coordinating Centers for DIPHR IDIQ supporting prenatal and childhood health disparities research with Total Small Business set-asides on select task orders.

Activity remains stable but with modest volatility: twenty-two awards in 2022 to twenty-seven in 2024, declining to eighteen awards in 2026 (year-to-date as of September 15, 2026). Thirty-eight awards worth $580.9 million in combined potential value face ultimate completion within the next twenty-four months, exposing the vendor to significant recompete activity in that window. Service Contract Inventory reporting shows SCI-reportable invoicing of $383.2 million across FY2022–FY2025, with government-paid labor ramping from $85.4 million in FY2022 to $122.7 million in FY2025 against relatively stable FTE footprints of 312–418 FTEs per fiscal year across SCI-reportable contracts. Government-paid hourly rates on SCI contracts run from a tenth-percentile low of $61.38 per hour to a ninetieth-percentile high of $222.54 per hour, with a median of $129.46 per hour, reflecting a mix of senior statistical and program management labor alongside project coordinators and data managers. Across SCI-reportable prime contracts, Emmes self-performed zero percent of labor through subcontractors, performing all reported hours in-house despite maintaining relationships with 20 named subcontractors across the federal portfolio.

Emmes operates as a subcontractor on vaccine development and clinical trials coordination work. The company subs to Weems Design Studio, Inc. and Leidos Biomed on the NIAID DMID H5N1 Vaccine clinical trial, providing data management and statistical analysis support for Investigational New Drug trials with validated 21 CFR Part 11 compliant systems. Emmes also subs to Gap Solutions, Inc., Digital Infuzion, LLC, and Regency Consulting Inc. on the CIVICS Statistical, Data Management and Coordination Center (SDMCC) program, delivering statistical design and analysis, clinical data management, EDC system training, and SMC/DSMB report generation. Sub-recipient relationships include the Medical College of Wisconsin for the Blood and Marrow Transplant Clinical Trials Network Data Coordinating Center and Cure Sickle Cell initiatives, and Trustees of Dartmouth College for the Northeast Node of the National Drug Abuse Treatment Clinical Trials Network. Emmes also acts as a subaward recipient under a federal grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) cooperative agreement for continuation of the Collaborative Islet Transplantation Registry Data and Statistical Coordinating Center (CITR-DSCC) through June 30, 2027.

Recent awards reflect sustained NIH engagement across diverse research domains. In September 2026, the National Institute of Allergy and Infectious Diseases awarded a $183.6 thousand purchase order for continued read-only access, maintenance, security compliance, and decommissioning of the Vaccine Research Center websites and associated data systems (ultimate completion September 14, 2027). The National Human Genome Research Institute issued multiple time-and-materials delivery orders in the June–July 2026 window for regulatory support for IND/IDE submissions ($33.7 thousand), Data Safety and Monitoring Board support ($23.9 thousand), and statistical expertise for the Small Business Research and Business initiative ($115 thousand). Emmes' track record demonstrates sustained capacity to manage complex, multi-year research infrastructure supporting NIH's clinical trial portfolio and genomic medicine missions. The company competes across full-and-open competitive sets; no set-asides characterize its prime federal work, and the vendor does not pursue or hold positions on government-wide acquisition contracts (GWACs) or civilian agency-wide schedules outside the NIH space.